Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HEXA | P06865 | 3/20 | 0.38 |
| ▸ | HEXB | P07686 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628085 | 0.90 | KDM4E (0.47) | KDM4EMEN1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL13628098 | 0.84 | HTR1A (0.49) | KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13628093 | 0.84 | MMP2 (0.45) | KDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL13628111 | 0.84 | PTPRC (0.43) | KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13628109 | 0.83 | CCNC (0.41) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL13628105 | 0.82 | MAPT (0.45) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL13628125 | 0.81 | HTT (0.41) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL13628119 | 0.79 | MAOB (0.40) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL13628107 | 0.72 | TRPA1 (0.50) | MAPT | |
| SCHEMBL13628084 | 0.71 | CHRM5 (0.38) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1175399-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) | VERTEX PHARMA (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | MAP3K1, JUN, MAP3K7 | KDM4E 2171/4885MEN1 4320/4885KMT2A 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.